Drugs for Down Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 537)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
5281004 40000 63006 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11Β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
AIRCORT
Bidien
BUDEFLAM AQUANASE
BUDELIN NOVOLIZER
BUDENOFALK
Budeson
Budesónida
BUDESONIDE
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budicort
CORTIMENT
Cortivent
Desowen
DEXBUDESONIDE
DUORESP SPIROMAX
ENTOCORT
ENTOCORT CR
Entocort ec
Entocort®|Eohilia® (budesonide oral suspension)|Jorveza®|Pulmicort®|S-1320|Uceris®
Horacort
MAP0010
|
MAP-0010
Micronyl
Noex
ORTIKOS
PREFERID
PULMAXAN
Pulmicort
PULMICORT FLEXHALER
PULMICORT L.S.
Pulmicort Nebuamp
PULMICORT RESPULES
Pulmicort Turbuhaler
R01AD05
Rhinocort
RHINOCORT ALLERGY
RHINOCORT AQUA
RHINOCORT AQUA 64
Rhinocort Turbuhaler
Rhinosol
S-1320
Spirocort
SYMBICORT
Tridesilon
Uceris
|
|
2 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
4659387 5311101 |
Synonyms:
ADVAIR
Advair®|Avamys®|Flovent HFA®|Veramyst®
FLOVENT HFA
Fluticason
|
Fluticasona
Fluticasone
Fluticasonum
VERAMYST
|
|
3 |
|
Oxytocin |
Approved, Vet_approved |
Phase 4 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
4 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
5 |
|
Memantine |
Approved, Investigational |
Phase 4 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
6 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 4 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
7 |
|
Petrolatum |
Approved, Investigational |
Phase 4 |
|
8009-03-8 |
|
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum
Petrolatum base
Petrolatum, white
Petrolatum,amber
|
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
|
|
8 |
|
Entecavir |
Approved, Investigational |
Phase 4 |
|
142217-69-4 |
153941 |
Synonyms:
ANHYDROUS ENTECAVIR
Baraclude
BMS-200475-01
Entecavir
ENTECAVIR (ANHYDROUS)
|
ENTECAVIR ANHYDROUS
ENTECAVIR HYDRATE
ENTECAVIR MONOHYDRATE
ENTECAVIRUM
SQ-34676
|
|
9 |
|
Telbivudine |
Approved, Investigational |
Phase 4 |
|
3424-98-4 |
159269 |
Synonyms:
1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
1-(2-Deoxy-beta-L-ribofuranosyl)-5-methyluracil
1-(2-Deoxy-b-L-ribofuranosyl)-5-methyluracil
1-(2-Deoxy-β-L-ribofuranosyl)-5-methyluracil
2'-Deoxy-L-thymidine
ABBR LDT
beta L 2' Deoxythymidine
beta-L-2'-Deoxythymidine
Beta-L-Thymidine
b-L-2'-Deoxythymidine
b-L-Thymidine
Epavudine
L-Deoxythymidine
|
LDT
L-DT
LDT600
LDT-600
L-Thymidine
NV-02B
SEBIVO
Telbivudin
Telbivudina
TELBIVUDINE
Tyzeka
Î’-L-2'-deoxythymidine
Î’-L-thymidine
|
|
10 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
11 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
12 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 4 |
|
54910-89-3 |
3386 |
Synonyms:
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Adofen
Animex-On
Deprex
Eufor
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
FLUOXETINE
Fluoxétine
Fluoxetine Hcl
Fluoxetine hydrochloride
|
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC-283480
Portal
Prozac
Prozac Weekly
Prozac®
Pulvules
Reneuron
Sarafem
Symbyax
|
|
13 |
|
Afatinib |
Approved |
Phase 4 |
|
439081-18-2, 850140-72-6 |
53445376 10184653 |
Synonyms:
AFATINIB
AFATINIBUM
BIBW 2992
BIBW2992
BIBW-2992
|
BIBW2992|Gilotrif®
GILOTRIF
GIOTRIF
Tomtovok
Tovok
|
|
14 |
|
Venlafaxine |
Approved |
Phase 4 |
|
99300-78-4, 93413-69-5 |
5656 |
Synonyms:
1-(2-(dimethylamino)-1-(4-Methoxyphenyl)ethyl)cyclohexanol HCL
1-[2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL]CYCLOHEXAN-1-OL
ALVENTA XL
AMPHERO XL
BONILUX XL
Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
DEPEFEX XL
Dobupal
Efectin
Efexor
EFEXOR XL
Effexor
EFFEXOR XR
Effexor®|WY-45030
Elafax
FORAVEN XL
Hydrochloride, venlafaxine
MENTAVEN XL
POLITID XL
RANFAXINE XL
RODOMEL XL
Sila venlafaxine
Sila-venlafaxine
SUNVENIZ XL
TARDCAPS XL
TIFAXIN XL
|
TONPULAR XL
Trevilor
TRIXAT XL
Vandral
VAXALIN XL
VENAXX XL
VENLABLUE XL
VENLADEX XL
Venlafaxin
Venlafaxina
Venlafaxina [INN-Spanish]
VENLAFAXINE
Venlafaxine [INN:Ban]
VENLAFAXINE HCL
Venlafaxine hydrochloride
Venlafaxinum
Venlafaxinum [INN-Latin]
Venlafexine
VENLALIC XL
VENLANEO XL
VENSIR XL
VEXARIN XL
VIEPAX
VIEPAX XL
WINFEX XL
WY-45030
|
|
15 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(−)-noradrenaline
(-)-Noradrenaline
(−)-norepinephrine
(-)-Norepinephrine
(-)-norepinephrine|Levarterenol®|noradrenaline
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-norepinephrine
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]PYROCATECHOL
Adrenor
Aktamin
Arterenol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
|
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-Arterenol
Levarterenol
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
L-noradrenaline
L-Norepinephrine
Noradrenalin
Noradrenaline
Nor-adrenaline
Norartrinal
Norepinefrina
Norepinephrine
Norépinéphrine
Norepinephrinum
Norepirenamine
Nor-epirenan
R-NOREPINEPHRINE
Sympathin E
|
|
16 |
|
Citalopram |
Approved |
Phase 4 |
|
59729-32-7, 59729-33-8 |
2771 |
Synonyms:
[<sup>3</sup>H]-citalopram
Akarin
Bonitrile
Celapram
Celexa
Celexa®|Cipramil®|LU-10171B
Celius
Ciazil
Cilift
Cipram
CIPRAMIL
Ciprapine
Citabax
Citadur
Citalec
Citalopram
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
Citopam
Citox
|
Citrol
Cytalopram
Dalsan
Elopram
Escitalopram
Escitalopram oxalate
Humorup
Lexapro
LU 10-171-B
LU-10-171-B
Nitalapram
Oropram
PAXORAN
Pramcit
Recital
Seropram
Talam
Talohexal
Temperax
Vodelax
Zentius
Zetalo
|
|
17 |
|
Dexetimide |
Withdrawn |
Phase 4 |
|
21888-98-2 |
30843 |
Synonyms:
(+)-BENZETIMIDE
(+)-benzetimide|R 16470|Tremblex®
Dexetimida
DEXETIMIDE
|
Dexetimidum
R 16470
R-16470 [AS HYDROCHLORIDE]
TREMBLEX
|
|
18 |
|
interferons |
|
Phase 4 |
|
|
|
19 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
20 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
21 |
|
Budesonide, Formoterol Fumarate Drug Combination |
|
Phase 4 |
|
|
|
22 |
|
Fluticasone-Salmeterol Drug Combination |
|
Phase 4 |
|
|
|
23 |
|
Xhance |
|
Phase 4 |
|
|
|
24 |
|
Formoterol Fumarate |
|
Phase 4 |
|
|
|
25 |
|
Salmeterol Xinafoate |
|
Phase 4 |
|
94749-08-3 |
|
Synonyms:
GR-33343 G
GR-33343-G
GR-33343X
LIPO-202
|
SALMETEROL 1-HYDROXY-2-NAPHTHOATE
SALMETEROL XINAFOATE
SEREVENT
|
|
26 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
27 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
28 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
29 |
|
Emollients |
|
Phase 4 |
|
|
|
30 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
31 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
32 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
33 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
34 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
35 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
36 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
37 |
|
Protein Kinase Inhibitors |
|
Phase 4 |
|
|
|
38 |
|
Mitogens |
|
Phase 4 |
|
|
|
39 |
|
Fingolimod Hydrochloride |
|
Phase 4 |
|
162359-56-0 |
|
Synonyms:
FINGOLIMOD
FINGOLIMOD HCL
FTY-720
|
FTY720 HYDROCHLORIDE
FTY-720 HYDROCHLORIDE
GILENYA
|
|
40 |
|
Serotonin and Noradrenaline Reuptake Inhibitors |
|
Phase 4 |
|
|
|
41 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
42 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
43 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
44 |
|
Tocopherol |
Approved, Investigational |
Phase 3 |
|
1406-66-2 |
|
Synonyms:
Methyltocols
tocoferol
tocoferoles
|
|
|
45 |
|
Sorafenib |
Approved, Investigational |
Phase 3 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
46 |
|
Levonorgestrel |
Approved, Investigational |
Phase 3 |
|
797-63-7 |
13109 |
Synonyms:
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one
(+-)-Norgestrel
(8R,9S,10R,13S,14S,17R)-13-ETHYL-17-ETHYNYL-17-HYDROXY- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- TETRADECAHYDROCYCLOPENTA[A] PHENANTHREN-3-ONE
13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13-b-Ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
13-Ethyl-17-a-ethynyl-17-b-hydroxy-4-gonen-3-one
13-Ethyl-17-a-ethynylgon-4-en-17-b-ol-3-one
13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
13-Ethyl-17-α-ethynyl-17-β-hydroxy-4-gonen-3-one
13-Ethyl-17-α-ethynylgon-4-en-17-β-ol-3-one
13-Β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one
17-a-Ethinyl-13-b-ethyl-17-b-hydroxy-4-estren-3-one
17a-Ethynyl-13b-ethyl-3-oxo-4-estren-17b-ol
17-a-Ethynyl-13-ethyl-19-nortestosterone
17a-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17a-Ethynyl-18-homo-19-nortestosterone
17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
17-alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-Ethynyl-18-homo-19-nortestosterone
17-Ethynyl-18-methyl-19-nortestosterone
17-Α-ethinyl-13-β-ethyl-17-β-hydroxy-4-estren-3-one
17-Α-ethynyl-13-ethyl-19-nortestosterone
17Α-ethynyl-13β-ethyl-3-oxo-4-estren-17β-ol
17Α-ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17Α-ethynyl-18-homo-19-nortestosterone
18-Methyl-17-a-ethynyl-19-nortestosterone
18-Methyl-17-alpha-ethynyl-19-nortestosterone
18-Methyl-17-α-ethynyl-19-nortestosterone
18-Methylnorethisterone
Alcala brand OF levonorgestrel
ATHENTIA NEXT
Aventis pharma brand OF levonorgestrel
BAY86-5028
Berlex brand OF levonorgestrel
Capronor
Cerazet
D Norgestrel
D(-)-Norgestrel
D-Norgestrel
Duofem
EMERRES
EMERRES UNA
EZINELLE
FALLBACK SOLO
HER STYLE
Hexal brand OF levonorgestrel
HRA brand 1 OF levonorgestrel
HRA brand 2 OF levonorgestrel
|
ISTERANDA
Jadelle
JAYDESS
KYLEENA
L Norgestrel
Levonelle
LEVONELLE ONE STEP
LEVONELLE-2
Levonorgestrel
LÉVONORGESTREL
Lèvonorgestrel
Levonorgestrel alcala brand
Levonorgestrel berlex brand
Levonorgestrel hexal brand
Levonorgestrel paladin brand
Levonorgestrel wyeth brand
Levonorgestrelum
Levonova
LEVOSERT
LILETTA
L-Norgestrel
l-norgestrel|Norplant®
Microlut
Microluton
Microval
Mirena
Norgeston
NORGESTREL (-)-FORM
NorLevo
Norplant
Norplant 2
NORPLANT II
NORPLANT SYSTEM
Norplant2
Norplant-2
OPCICON ONE-STEP
Ovrette
Paladin brand OF levonorgestrel
Plan b
PLAN B ONE-STEP
Postinor
POSTINOR-2
Schering brand 1 OF levonorgestrel
Schering brand 2 OF levonorgestrel
Schering brand 3 OF levonorgestrel
SKYLA
UPOSTELLE
Vikela
Women's capital brand OF levonorgestrel
WY-3707
WY-5104
Wyeth brand OF levonorgestrel
|
|
47 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 3 |
|
50-28-2 |
5757 |
Synonyms:
(+)-3,17B-ESTRADIOL
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17BETA)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(17Î’)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(1S,10R,11S,14S,15S)-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
(8R,9S,13S,14S,17S)-13-METHYL-6,7,8,9,11,12,14,15,16,17-DECAHYDROCYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
[<sup>3</sup>H]-estradiol|[<sup>3</sup>H]-estrogen|[<sup>3</sup>H]E2|[<sup>3</sup>H]estradiol
13B-METHYL-1,3,5(10)-GONATRIENE-3,17B-OL
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17B-ESTRADIOL
17BETA OESTRADIOL
17BETA-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17BETA-ESTRADIOL
17BETA-OESTRADIOL
17B-OESTRADIOL
17Î’ oestradiol
17Î’-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17β-estradiol
17Î’-OESTRADIOL
3,17B-DIHYDROXYESTRA-1,3,5(10)-TRIENE
3,17B-ESTRADIOL
3,17-EPIDIHYDROXYESTRATRIENE
ADGYN ESTRO
AERODIOL
AGOFOLLIN
ALFATRADIOL
ALORA
ALTRAD
AMNESTROGEN
AQUADIOL
AQUAGEN
BARDIOL
BEDOL
B-ESTRADIOL
BETA-ESTRADIOL
CIS-ESTRADIOL
CLIMADERM
CLIMARA
CLIMARA PRO
COMPUDOSE
CORPAGEN
Delestrogen
DELTA-ESTRADIOL
DELTA-OESTRADIOL
DEPO-ESTRADIOL
DERMESTRIL
DERMESTRIL 100
DERMESTRIL 25
DERMESTRIL 50
DERMESTRIL SEPTEM 25
DERMESTRIL SEPTEM 50
DERMESTRIL SEPTEM 75
DESTRADIOL
D-ESTRADIOL
DIHYDROFOLLICULAR HORMONE
DIHYDROFOLLICULIN
DIHYDROMENFORMON
DIHYDROTHEELIN
DIHYDRO-THEELIN
DIHYDROXYESTRIN
DIMENFORMON
DIOGYN
DIOGYNETS
DIVIGEL
D-OESTRADIOL
E2
E2|estrogen|oestrodiol|oestrogen
E-CYPIONATE
ELESTRIM
ELESTRIN
ELLESTE SOLO
ELLESTE SOLO MX 40
ELLESTE SOLO MX 80
ENCORE
EPIESTRIOL 50
ESCLIM
ESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
ESTRACE
ESTRADERM
ESTRADERM MX 100
ESTRADERM MX 25
ESTRADERM MX 50
ESTRADERM MX 75
ESTRADERM TTS
ESTRADERM TTS 100
ESTRADERM TTS 25
ESTRADERM TTS 50
ESTRADIOL
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
ESTRADIOL HEMIHYDRATE
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol valerate
Estradiol valeriante
|
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17b
ESTRADIOL-17BETA
ESTRADIOL-17-BETA
Estradiol-17β
ESTRADIOLUM
ESTRADOT
ESTRALDINE
ESTRASORB
ESTRING
ESTRING VAGINAL RING
ESTROCLIM
ESTROCLIM 50
ESTROGEL
ESTROGEL HBF
ESTROGEN
ESTROVITE
EVAMIST
EVOREL
EVOREL 100
EVOREL 25
EVOREL 50
EVOREL 75
FEMATRIX 40
FEMATRIX 80
FEMESTRAL
FEMOGEN
FEMPATCH
FEMSEVEN 100
FEMSEVEN 50
FEMSEVEN 75
FOLLICYCLIN
GELESTRA
GINOSEDOL
GVNODIOL
GYNERGON
GYNODIOL
GYNOESTRYL
GYNOGEN
IMVEXXY
INNOFEM
LAMDIOL
MACRODIOL
MENOREST
MENOREST 37.5
MENOREST 50
MENOREST 75
MENORING 50
MENOSTAR
MINIVELLE
NORDICOL
Novartis pharmaceuticals brand OF estradiol
NSC-20293
NSC-9895
OESCLIM
OESTERGON
OESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
OESTRADIOL
OESTRODIOL
OESTROGEL
OESTROGEN
OESTROGLANDOL
Orion brand OF estradiol
OVAHORMON
OVASTEROL
OVASTEVOL
OVOCYCLIN
OVOCYLIN
PERLATANOL
PRIMOFOL
PROFOLIOL
PROFOLIOL B
PROGYNON
Progynon depot
PROGYNON DH
Progynon-depot
Progynova
PROGYNOVA TS
SANDRENA
SANDRENA 1
SYNDIOL
SYSTEN
VAGIFEM
VAGIFEM 18
VAGIFEM 8
VIVELLE
VIVELLE-DOT
WC3011
WC-3011
ZUMENON
Î’-estradiol
|
|
48 |
|
Ethinylestradiol |
Approved |
Phase 3 |
|
57-63-6 |
5991 |
Synonyms:
(1S,10R,11S,14R,15S)-14-ETHYNYL-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
17 ALPHA-ETHINYLESTRADIOL
17 ALPHA-ETHYNYLESTRADIOL
17 ALPHA-ETHYNYLOESTRADIOL
17α-ethynylestradiol|ethinyl estradiol
17a-Ethinyl estradiol
17a-Ethinyl-17b-estradiol
17a-Ethinylestradiol
17a-Ethynyl-17b-oestradiol
17a-Ethynylestradiol-L7b
17a-Ethynyloestradiol
17a-Ethynyloestradiol-17b
17alpha-Ethinyl estradiol
17-Ethinyl-3,17-estradiol
17-Ethinyl-3,17-oestradiol
17-Ethinylestradiol
17-Ethynylestradiol
17-Ethynylestradiol ram
17-Ethynyloestradiol
17Α-ethinyl estradiol
17Α-ETHYNYLESTRADIOL
Alora
Amenoron
Anovlar
Chee-O-gen
Chee-O-genf
Diognat-e
Diogyn e
Diogyn-e
Dyloform
Effik brand OF ethinyl estradiol
ENOVID
ENOVID-E
Ertonyl
Esclim
Esteed
Estigyn
Estinyl
Eston-e
Estoral
Estoral {[orion]}
Estorals
Estradiol, ethinyl
Estradiol, ethynyl
Estring
Estrogen
Ethidol
Ethinoral
Ethinyl estradiol
Ethinyl estradiol hemihydrate
Ethinyl estradiol, (8 alpha)-isomer
Ethinyl estradiol, (8 alpha,17 alpha)-isomer
Ethinyl estradiol, (8 alpha,9 beta,13 alpha,14 beta)-isomer
Ethinyl estradiol, (9 beta,17 alpha)-isomer
Ethinyl oestradiol effik
Ethinylestradiol
Ethinylestradiol jenapharm
ETHINYLESTRADIOLUM
Ethinylestriol
Ethinyloestradiol
|
Ethinyl-oestradiol effik
ETHINYL-OESTRANOL
Ethynyl estradiol
Ethynylestradiol
ETHYNYLOESTRADIOL
Eticyclin
Eticyclol
Eticylol
Etinestrol
Etinestryl
ETINILESTRADIOL
Etinoestryl
Etistradiol
Etivex
Feminone
Fempatch
Follicoral
Ginestrene
Gynodiol
Gynolett
Hemihydrate, ethinyl estradiol
Inestra
Innofem
Jenapharm brand OF ethinyl estradiol
Jenapharm, ethinylestradiol
Kolpolyn
Linoral
Lynoral
Menolyn
Menostar
Microfollin
Microfollin forte
Neo-estrone
Nogest-S
NORINYL
Novestrol
NSC-10973
Oradiol
Orestralyn
Orestrayln
Organon brand OF ethinyl estradiol
Ovex
OVULEN
OVULEN-21
OVULEN-28
Palonyl
Perovex
Primogyn
Primogyn C
Primogyn m
Progynon C
Progynon m
Schering brand OF ethinyl estradiol
Schering-plough brand OF ethinyl estradiol
Spanestrin
Thiuram e
Thiuranide
Vagifem
Ylestrol
|
|
49 |
|
Polyestradiol phosphate |
Approved |
Phase 3 |
|
28014-46-2 |
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
ESTRADIOL PHOSPHATE
Estradiol phosphate polymer
ESTRADURIN
Fosfato de poliestradiol
LEO-114
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
POLYEST PHOS
POLYESTRADIOL PHOS PHOSPHATE
POLYESTRADIOL PHOSPHATE
Polyestradioli phosphas
|
|
50 |
|
Norgestrel |
Approved |
Phase 3 |
|
6533-00-2 |
|
Synonyms:
17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one
LD norgestrel
Methylnorethindrone
NORGESTREL
Norgestrelum
OPILL
OVRETTE
|
PREFEST
PREVIFEM
SPRINTEC
TRI-PREVIFEM
TRI-SPRINTEC
WY-3707
|
|
Interventional clinical trials:
(show top 50)
(show all 695)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT |
Unknown status |
NCT02027064 |
Phase 4 |
Interferon-alpha |
2 |
A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP) |
Unknown status |
NCT02708446 |
Phase 4 |
Mifepristone;Buccal misoprostol;Sublingual misoprostol |
3 |
Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS. |
Unknown status |
NCT00867737 |
Phase 4 |
Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI |
4 |
The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail |
Unknown status |
NCT02336568 |
Phase 4 |
Oxytoine;PLACEBO |
5 |
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study |
Unknown status |
NCT02404675 |
Phase 4 |
icotinib |
6 |
A Sixteen-Week, Randomized, Double Blind, Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Young Adults With Down Syndrome |
Completed |
NCT01112683 |
Phase 4 |
Memantine;Placebo |
7 |
A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule |
Completed |
NCT01349829 |
Phase 4 |
|
8 |
Evaluation of the Safety and Efficacy of the Product Bepantol® Derma Spray After the Dermatological Procedure in the Face - 21 Days of Follow-up. |
Completed |
NCT03853538 |
Phase 4 |
BAY207543 (Bepanthol, Bepantol® Derma Spray) |
9 |
Safety and Efficacy Evaluation of the Use of Bepantol® Derma Spray After Laser Depilation in the Inguinal Region in Adult Women - 21 Days Use at Home |
Completed |
NCT03853525 |
Phase 4 |
BAY207543 (Bepanthol, Bepantol® Derma Spray) |
10 |
Safety Assessment, Instrumental and Perceived Efficacy 21 Days of Use at Home - Bepantol Derma Spray® Dermal and Gynecological Acceptability Assessment. |
Completed |
NCT03853512 |
Phase 4 |
BAY207543 (Bepanthol, Bepantol® Derma Spray) |
11 |
An Extension to A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB) (An Open-label Multicenter, follow-on Trial of the Safety of Oral Administration of Telbivudine (LDT600) 600 mg Over 21 Months in Adults With HBeAg-positive Ompensated Chronic Hepatitis B (CHB)) |
Completed |
NCT00467545 |
Phase 4 |
telbivudine |
12 |
A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations |
Completed |
NCT02514174 |
Phase 4 |
Afatinib |
13 |
Fluoxetine Treatment of Depression in Adults With Down Syndrome |
Recruiting |
NCT05458479 |
Phase 4 |
Fluoxetine |
14 |
Low Interventional Cohort Study of Myocarditis/Pericarditis Associated With COMIRNATY in Persons Less Than 21 Years of Age |
Not yet recruiting |
NCT05295290 |
Phase 4 |
|
15 |
Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients |
Terminated |
NCT04747275 |
Phase 4 |
Oral tablet levothyroxine (L-T4);Liquid stable levothyroxine (L-T4) Tirosint-SOL |
16 |
An Open-label, Single-arm Phase IV Study of Afatinib in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Who Have Poor Performance Status and Whose Tumors Have the Common Epidermal Growth Factor Receptor (EGFR) Mutations, Exon 19 Deletions or Exon 21(L858R) Substitution Mutations |
Terminated |
NCT02695290 |
Phase 4 |
Afatinib |
17 |
A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression |
Terminated |
NCT01436643 |
Phase 4 |
Venlafaxine;Fluoxetine;Citalopram;Fingolimod |
18 |
Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix® (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114) |
Withdrawn |
NCT02124785 |
Phase 4 |
|
19 |
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome |
Unknown status |
NCT00056329 |
Phase 3 |
Vitamin E;multivitamin;Placebo |
20 |
Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation |
Unknown status |
NCT00005052 |
Phase 3 |
|
21 |
A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL |
Unknown status |
NCT00129090 |
Phase 3 |
R-CHOEP 14 with 12x Rituximab |
22 |
Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04 |
Unknown status |
NCT00207636 |
Phase 3 |
|
23 |
A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING) |
Unknown status |
NCT01407822 |
Phase 2, Phase 3 |
Erlotinib;Gemcitabine/cisplatin |
24 |
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome |
Completed |
NCT01594346 |
Phase 3 |
Alpha-Tocopherol;Sugar Pill |
25 |
One-year Double-blind Placebo-controlled Phase 2-3 Study to Evaluate the Effect of Oral Folinic Acid Treatment (1mg/kg/d) on the Psychomotor Development of Young Down Syndrome Patients |
Completed |
NCT00294593 |
Phase 2, Phase 3 |
folinic acid |
26 |
Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children |
Completed |
NCT01576705 |
Phase 3 |
thyroid hormone and folinic acid |
27 |
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years |
Completed |
NCT00369317 |
Phase 3 |
asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide |
28 |
Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study |
Completed |
NCT00003593 |
Phase 3 |
asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine |
29 |
Study to Compare the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted HBV Vaccine (0, 21-day Schedule) to a Double Dose of Engerix™ -B (0, 7, 21-day Schedule), in Pre-liver Transplant Patients ≥ 18 y, Boosted at Month 6-12 |
Completed |
NCT00697554 |
Phase 3 |
|
30 |
Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] |
Completed |
NCT00278408 |
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate |
31 |
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma |
Completed |
NCT00003644 |
Phase 3 |
carboplatin;paclitaxel |
32 |
A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months |
Completed |
NCT04074928 |
Phase 3 |
|
33 |
A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea |
Completed |
NCT01659853 |
Phase 3 |
CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15% |
34 |
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01318733 |
Phase 3 |
CD07805/47 gel 0.5% |
35 |
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea |
Completed |
NCT01789775 |
Phase 3 |
Drug: CD07805/47 gel;CD07805/47 gel Placebo |
36 |
A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01355471 |
Phase 3 |
CD07805/47 Gel;Placebo |
37 |
A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01355458 |
Phase 3 |
CD07805/47 gel;Placebo |
38 |
A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta(R), Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia |
Completed |
NCT02044276 |
Phase 3 |
lipegfilgrastim;pegfilgrastim |
39 |
A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury |
Completed |
NCT00843492 |
Phase 3 |
Fondaparinux sodium;Nadroparin |
40 |
A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease |
Completed |
NCT00372697 |
Phase 3 |
Octreotide acetate 30 mg suspension |
41 |
A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus |
Completed |
NCT02585674 |
Phase 3 |
Insulin glargine (U300) |
42 |
A Randomized, Open-label, Multi-center Phase III Study of Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With EGFR Exon 19 or 21 Mutation (Optimal) |
Completed |
NCT00874419 |
Phase 3 |
erlotinib;gemcitabine/carboplatin |
43 |
An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) |
Completed |
NCT00629031 |
Phase 3 |
Paromomycin |
44 |
Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. |
Completed |
NCT00144755 |
Phase 3 |
Darbepoetin alfa |
45 |
A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms |
Completed |
NCT00043147 |
Phase 3 |
beclomethasone dipropionate;methylprednisolone;prednisone |
46 |
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women |
Completed |
NCT00920985 |
Phase 3 |
Gestodene/EE (FC Patch Low, BAY86-5016);Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A |
47 |
A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer |
Completed |
NCT00003088 |
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;paclitaxel |
48 |
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects |
Completed |
NCT00910637 |
Phase 3 |
Gestodene/EE Patch (BAY86-5016) |
49 |
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects |
Completed |
NCT00914693 |
Phase 3 |
Ethinylestradiol/Gestodene (BAY86-5016) |
50 |
Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months. |
Completed |
NCT00351923 |
Phase 3 |
|
Cochrane evidence based reviews: down syndrome
|